• Tuesday, October 22nd
  • like us on facebook
  • like us on facebook
 

Reports

PMPRB annual report: 2012

Tabled in Parliament on October 16, 2013… Read on: Patent Medicine Prices Review Board

 

Policy Brief: CETA and Intellectual Property – The debate over pharmaceutical patents

Read on: Carelton.ca

 

Patient suffering could be reduced by accepting European or U.S. prescription drug approvals

CALGARY, AB—Canadian patients are denied the health benefits of many new medicines for months, if not years, waiting for their government to duplicate approvals already provided in other jurisdictions, concludes a new study published today...

 

Wrong Prescription: The Unintended Consequences of Pharmaceutical Cost Containment Policies

The obsession with reducing public spending on prescription drugs, which takes the form of constantly falling price caps, bulk purchasing strategies and reimbursement restrictions, entails numerous unintended consequences, especially for the...

 

Canadian Health Policy Since Romanow: Easy to Call for Change, Hard to Do

High-level health policy is a national preoccupation in Canada. Health policy implementation is another story. There has long been widespread endorsement of broad system goals; the reports produced through 2002, reviewed by Fooks and Lewis,...

 

Technological Innovation in Healthcare: Report of the Standing Committee on Health

Technological Innovation in Healthcare: Report of the Standing Committee on Health (HESA) June 2013  

 

2013 Spring Report of the Auditor General of Canada

The link below is a direct link to chapter 5 of the Auditor General report which focusses on Diabetes… Chapter 5—Promoting Diabetes Prevention and Control  

 

Senate Committee Releases its Report on Post-Approval Monitoring of Pharmaceuticals

Senate Committee Releases its Report on Post-Approval Monitoring of Pharmaceuticals

Ottawa (March 26, 2013) – Canada needs to improve and modernize the monitoring of drugs that have already been approved and are in use currently, says a report entitled Prescription Pharmaceuticals in Canada: Post-Approval Monitoring of...

 

New Pharmacare program tied entirely to family income

Cutting the price it pays for generic drugs by half and introducing means testing for supplementary health benefits is expected to save the Alberta government $270 million a year. But the big changes announced in this week’s provincial...

 

How do Canadian primary care physicians rate the health system?

This bulletin examines Canadian primary care physicians’ views on health system performance in 2012, with comparisons to similar surveys in 2006 and 2009. Wide variations exist across Canada, pointing to the potential for improvement. While...

 

Fraser Institute survey shows Alberta still trailing in medical wait times

Reductions in medical wait times have been more underwhelming in Alberta than in most other provinces, according to a right-wing think tank. Alberta stories

 

Waiting Your Turn: Wait Times for Health Care in Canada, 2012 Report

This edition of Waiting Your Turn indicates that waiting times for elective medical treatment have decreased since last year. Specialist physicians surveyed across 12 specialties and 10 Canadian provinces report a total waiting time of 17.7...

 

Drugs and the public cost of health care in Canada: Report

Non-factual assertions about the impact of drug costs (esp. patented medicines) on the growth of health spending have the potential to misinform important policy decisions of Canadian governments including pending proposals for national pharmacare,...

 

International Profiles of Health Care Systems: Australia, Canada, Denmark, England, France, Germany, Japan, Iceland, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States

International Profiles of Health Care Systems: Australia, Canada, Denmark, England, France, Germany, Japan, Iceland, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States

This publication presents overviews of the health care systems of Australia, Canada, Denmark, England, France, Germany, Japan, Iceland, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States. Each overview covers...

 

Canada’s Clinical Trial Infrastructure: A Prescription for Improved Access to New Medicines

Ottawa (November 1, 2012) – The absence of a standardized approach to research ethics review significantly impacts the time required to start up clinical trials in Canada and restricts the reporting of data in an open and transparent process....